Key result
Review highlights regulatory pathways and molecular mechanisms shaping emerging concepts in LDLR biology.
This review summarizes the pathways regulating the LDL receptor and emerging concepts in LDLR biology, which is the primary target for approved lipid-lowering medications.
Clearance of circulating plasma LDL (low-density lipoprotein) cholesterol by the liver requires hepatic LDLR (low-density lipoprotein receptor). Complete absence of functional LDLR manifests in severe hypercholesterolemia and premature atherosclerotic cardiovascular disease. Since the discovery of the LDLR 50 years ago by Brown and Goldstein, all approved lipid-lowering medications have been aimed at increasing the abundance and availability of LDLR on the surface of hepatocytes to promote the removal of LDL particles from the circulation. As such a critical regulator of circulating and cellular cholesterol, it is not surprising that LDLR activity is tightly regulated. Despite over half a century's worth of study, there are still many facets of LDLR biology that remain unexplored. This review will focus on pathways that regulate the LDLR and emerging concepts of LDLR biology.
No takes yet. Share an insight, caveat, or question.
Schmidt et al. (2025) conducted a review in Hypercholesterolemia and atherosclerotic cardiovascular disease. LDL Receptor Regulation was evaluated. This review focuses on the pathways and molecular mechanisms that regulate the low-density lipoprotein receptor (LDLR) and emerging concepts of LDLR biology.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: